SEC Form 4 · accession 0001209191-18-020566

Foundation Medicine, Inc. · FMI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Financial Officer

Period of report

Mar 15, 2018

Accepted (ET)

Mar 19, 2018 · 4:17 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001488613

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 15, 2018	M	7,147	$29.63	A	56,377	D
Common Stock^F1,F2	Mar 15, 2018	S	7,147	$78.26	D	49,230	D
Common Stock	Mar 15, 2018	M	7,853	$29.63	A	57,083	D
Common Stock^F1,F2	Mar 15, 2018	S	7,853	$78.26	D	49,230	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Common Stock (right to buy)^F3	$29.63	Mar 15, 2018	M	7,147	D	—	Feb 6, 2024	Common Stock	7,147	0	D
Common Stock (right to buy)^F3	$29.63	Mar 15, 2018	M	7,853	D	—	Feb 6, 2024	Common Stock	7,853	0	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017.
F2The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.50 to $79.45, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
F3This option was granted on February 6, 2014 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018.